Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $275
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Gary Nachman maintains an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and raises the price target from $242 to $275.
August 02, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James analyst Gary Nachman maintains an Outperform rating on Alnylam Pharmaceuticals and raises the price target from $242 to $275.
The raised price target and maintained Outperform rating from a reputable analyst at Raymond James is likely to positively impact Alnylam Pharmaceuticals' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100